John Smither Sells 1,600 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director John Smither sold 1,600 shares of the firm’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $25.32, for a total transaction of $40,512.00. Following the completion of the transaction, the director directly owned 8,760 shares in the company, valued at approximately $221,803.20. The trade was a 15.44% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

NewAmsterdam Pharma Stock Performance

NAMS traded down $2.84 during midday trading on Wednesday, reaching $22.79. 2,317,939 shares of the company were exchanged, compared to its average volume of 1,058,457. The company’s fifty day moving average price is $29.34 and its 200 day moving average price is $31.45. The company has a market cap of $2.72 billion, a price-to-earnings ratio of -10.55 and a beta of 0.09. NewAmsterdam Pharma Company N.V. has a one year low of $22.34 and a one year high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Wednesday, August 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. The company had revenue of $3.70 million during the quarter, compared to the consensus estimate of $2.83 million. As a group, sell-side analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.82 earnings per share for the current fiscal year.

Institutional Trading of NewAmsterdam Pharma

Several hedge funds have recently added to or reduced their stakes in NAMS. Wells Fargo & Company MN grew its position in shares of NewAmsterdam Pharma by 50.0% during the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after acquiring an additional 300 shares during the period. KBC Group NV bought a new stake in shares of NewAmsterdam Pharma in the 1st quarter worth approximately $37,000. Navalign LLC purchased a new position in NewAmsterdam Pharma in the fourth quarter valued at approximately $46,000. Empowered Funds LLC purchased a new position in NewAmsterdam Pharma in the fourth quarter valued at approximately $85,000. Finally, AdvisorNet Financial Inc bought a new position in NewAmsterdam Pharma during the first quarter valued at $82,000. Institutional investors own 89.89% of the company’s stock.

Analyst Upgrades and Downgrades

NAMS has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Friday, July 17th. Jefferies Financial Group restated a “buy” rating and set a $45.00 price target on shares of NewAmsterdam Pharma in a report on Monday, July 20th. Royal Bank Of Canada reduced their price objective on shares of NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. BMO Capital Markets initiated coverage on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. They issued an “outperform” rating and a $58.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $52.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.73.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.